Antiva raises $22M series C round

Antiva Biosciences Inc. (Menlo Park, Calif.) raised $22 million in a series C round led by new investor Brace Pharma Capital. Also participating were new investors NS Investment, Osage University Partners and Alexandria Venture Investments and existing investors Canaan Partners and Sofinnova Ventures.

Antiva is developing topical therapeutics to treat pre-cancerous lesions associated with HPV infection. President and CEO Gail Maderis told BioCentury that Antiva expects results by YE18 from Phase Ib studies of lead compound ABI-1968 to treat high-grade cervical intraepithelial neoplasia (CIN) and anal intraepithelial neoplasia (AIN). Antiva also plans to develop the topical antiviral to treat head and neck cancer...